An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma

NCT00492986 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1150

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Renal Cell

Interventions

DRUG: Nexavar (Sorafenib, BAY43-9006)

Sponsor

Bayer